Abstract
Patients on ICI therapy rarely experience life-threatening myocarditis, but little is currently known about the risk of other major adverse cardiac events (MACE) in this population. A retrospective study finds that 10% of patients, mostly with advanced cancers, experience MACE, with those with preexisting poor cardiovascular health being at greater risk.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.